You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Non-invasive method to evaluate the quality of human oocytes and embryos
SBC: Renova Life Inc. Topic: NICHDDESCRIPTION (provided by applicant): Project Summary We propose to develop a non-invasive method to predict mammalian oocyte quality by analyzing the surrounding cumulus cells' gene expression patterns (cGEP). The result of the cGEP assay---a cGEP score---can be used to predict embryo quality and ultimately the embryo transfer (ET) results. This technology, if success, will for the first time ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Remote focusing through spatial light modulation for multifocal multiphoton micro
SBC: BOULDER NONLINEAR SYSTEMS, INC. Topic: NIMHDESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Carisbamate Treatment for Alcohol Dependence
SBC: Medication Discovery Texas, Inc Topic: NIAAADESCRIPTION (provided by applicant): Though not specifically FDA-approved for this indication, topiramate is among the most effective medication treatments for alcohol dependence. Topiramate is rarely used to treat alcohol dependence, however, because it has prominent side effects including somnolence, dizziness, and cognitive disturbances that require gradual dose titration. Many patients stop ta ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Carisbamate Treatment for Alcohol Dependence
SBC: Medication Discovery Texas, Inc Topic: NIAAADESCRIPTION (provided by applicant): Though not specifically FDA-approved for this indication, topiramate is among the most effective medication treatments for alcohol dependence. Topiramate is rarely used to treat alcohol dependence, however, because it has prominent side effects including somnolence, dizziness, and cognitive disturbances that require gradual dose titration. Many patients stop ta ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Position tracking and mobility assessment system for indoor monitoring of elders
SBC: EMBEDRF LLC Topic: NIADESCRIPTION (provided by applicant): The goal of this project is to develop and evaluate a position tracking and mobility assessment system that will enable the elderly to live longer and more safely at home or in an assisted living facility. The ability to move is a critical function tat underlies the quality of life for the elderly. Changes in mobility such as speed of walking have been shown to ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Alafair Biosciences develops cross-linked polysaccharide hydrogel films to addres
SBC: ALAFAIR BIOSCIENCES, INC. Topic: NIGMSDESCRIPTION (provided by applicant): The goal of this STTR project is to develop a pre-formed, naturally-based hydrogel postoperative adhesion barrier with improved handling characteristics, laparoscopic deliverability, and consistent efficacy. Our technology is based on a novel, patented process that imparts exceptional elasticity and toughness on normally brittle, weak materials. Postoperative a ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
IYG-Family: Beyond the talk to effective pregnancy, STI, and HIV prevention
SBC: Radiant Creative Group, LLC Topic: NICHDDESCRIPTION (provided by applicant): The goal of this 3 year Fast-Track STTR is to develop and evaluate a home-based intervention ('it's Your Game- Family') to provide age-appropriate sexual health life skills education and training for children (11-14 years) and to enhance parents' skills and self-confidence in support of this training. IYG-Family (IYG-F) will be an on-line g ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Development of a Biochemical Diagnosis for Creutzfeldt-Jakob disease
SBC: Amprion, Inc. Topic: NINDSDESCRIPTION (provided by applicant): Human prion diseases are infectious and invariably fatal forms of neurodegenerative diseases, including sporadic Creutzfeldt-Jakob disease (sCJD), the most common form, and variant CJD (vCJD) which is associated to consumption of cattle meat infected by bovine spongiform encephalopathy. Currently there is not sensitive, objective and non-invasive biochemical di ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health